TABLE 1.
Baseline characteristics of patients
| Characteristic | N (%) or median (IQR) |
|---|---|
| Patients | n = 213 |
| Age, years (median [IQR]) | 62 (56–65) |
| Sex (n, %) | |
| Male | 179 (84) |
| Female | 34 (16) |
| ASA score (n, %) | |
| 1–2 | 112 (52.6) |
| 3–4 | 101 (47.4) |
| Diabetes (n, %) | |
| No | 141 (66.2) |
| Yes | 72 (33.8) |
| Metformin treatment (n, %) | 39 (18.3) |
| Statin treatment (n, %) | 32 (15) |
| BMI (kg/m2) | 27 (24–30) |
| Prior curative treatment (n, %) | |
| Naive patient | 98 (46) |
| Yes | 115 (54) |
| Liver disease | |
| Cirrhosis (n, %) | |
| No | 15 (7) |
| Yes | 198 (93) |
| Causes of liver disease (n, %) | |
| Alcohol | 132 (62%) |
| Viral hepatitis B or C | 46 (21.6%) |
| Other liver disease | 35 (16.4) |
| Steatosis (n, %) | |
| Absent | 140 (65.7) |
| Present | 73 (34.3) |
| MRI quantification, % (median [IQR]) | 3 (2–6) |
| Child‐Pugh class (n, %) | |
| A | 208 (97.7%) |
| B | 5 (2.3) |
| MELD score (median [IQR]) | 8 (7–10) |
| Laboratory data (median [IQR]) | |
| AFP (ng/ml) | 5.7 (3.4–11.45) |
| AFP > 100 ng/ml (n, %) | |
| Total bilirubin (μmol/L) | 11.7 (8–18) |
| Albumin (g/L) | 40.8 (38–43.7) |
| Prothrombin activity (%) | 83 (72–97) |
| AST (UI/ml) | 34.5 (24–48) |
| ALT (UI/ml) | 27 (19–38) |
| GGT (UI/ml) | 100.5 (51–222) |
| Platelet count (×10/mm3) | 122 (81–174) |
| Neutrophils (×10/mm3) | 3.35 (2.35–4.07) |
| Lymphocytes (×10/mm3) | 1.42 (1.05–2.03) |
| Monocytes (×10/mm3) | 0.52 (0.28–0.67) |
| Creatinine (μmol/L) | 72 (63–85) |
| ALBI score | |
| 1 | 144 (72) |
| 2 | 56 (28) |
| HCC | |
| Tumor size (median [IQR]) | 16 (13–20) |
| <20 mm | 173 (81.2%) |
| >20 mm | 40 (18.8%) |
| No. of nodules per patient (n, %) | |
| 1 | 157 (73.7%) |
| 2 | 42 (19.7%) |
| 3 | 14 (6.6%) |
| At least one biopsy‐proven nodule (n, %) | 47 (22) |
| Steatotic HCC (n, %) | 40 (18.8) |
| Subcapsular location (n, %) | 80 (37.6) |
| PTA | |
| PTA modality (n, %) | |
| Radiofrequency | 103 (48.4) |
| Microwave | 110 (51.6) |
| Imaging guidance (n, %) | |
| US guidance | 112 (52.6) |
| CT guidance | 101 (47.4) |
Note: Unless otherwise indicated, results are expressed as numbers (percentages).
Abbreviations: ALBI, albumin‐bilirubin; ALT, alanine aminotransferase; ASA, American Society of Anesthesiologists; AST, aspartate aminotransferase; BMI, body mass index; CT, computed tomography; GGT, gamma‐glutamyltransferase; IQR, interquartile range; MELD, Model for End‐Stage Liver Disease; MRI, magnetic resonance imaging; SIR, Society of Interventional Radiology; US, ultrasonography.